---
title: 'Bictegravir/emtricitabine/tenofovir alafenamide in clinical practice for people
  with HIV: final 24-month effectiveness and safety outcomes in key populations in
  the observational BICSTaR cohort'
date: '2025-02-12'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39936702/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20250212170950&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: 'CONCLUSIONS: B/F/TAF was generally well tolerated over 24 months, with
  high effectiveness and persistence observed among a broad range of people with ...'
disable_comments: true
---
CONCLUSIONS: B/F/TAF was generally well tolerated over 24 months, with high effectiveness and persistence observed among a broad range of people with ...